1. Acute pancreatitis in an ulcerative colitis patient treated with vedolizumab and budesonide.
- Author
-
Ravn CD, Bendix M, and Lyhne S
- Subjects
- Humans, Male, Adult, Acute Disease, Anti-Inflammatory Agents adverse effects, Anti-Inflammatory Agents therapeutic use, Glucocorticoids therapeutic use, Glucocorticoids adverse effects, Colitis, Ulcerative drug therapy, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Pancreatitis chemically induced, Budesonide adverse effects, Budesonide therapeutic use, Gastrointestinal Agents adverse effects, Gastrointestinal Agents therapeutic use
- Abstract
Acute pancreatitis (AP) is a sudden inflammation of the pancreas which often manifests as a mild disease but can be associated with high morbidity and mortality. Drug-induced AP is rare and most likely underdiagnosed. Vedolizumab is a human monoclonal antibody with gut-selective integrin antagonist effect, and it is used for treatment of inflammatory bowel disease (IBD). Budesonid is a glucocorticoid which is released in the colon and it is also used in IBD treatment. This is a case report where vedolizumab or budesonide caused acute pancreatitis in a young man with ulcerative colitis., (Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.)
- Published
- 2024
- Full Text
- View/download PDF